CORDIS
EU research results

CORDIS

English EN
Metastatic tumours facilitated by hypoxic tumour micro-environments

Metastatic tumours facilitated by hypoxic tumour micro-environments

Objective

Recent research suggests that the hypoxic micro-environment of tumours is one of the major drivers of metastatic spread of cancer. Furthermore, hypoxic tumour micro-environments may result in treatment resistance of cancer cells, therefore causing a double effect of reducing the potential of a successful treatment of the cancer patient. This project seeks to clarify the roles and functions of the hypoxic tumour micro-environment in relation to the survival of solid tumours likely to metastasise. We will gain new knowledge about molecular mechanisms behind hypoxia-driven metastasis, like the epithelial-mesenchymal transition (EMT) by several routes: (a): mechanisms related to cell growth- and cell proliferation (UPR, mTOR, CA9, HIF, Notch, and VHL), (b): angiogenesis and lymphangiogenesis, (c): metabolism and pH-regulation (d): the handling of reactive oxygen species (ROS). We will generate animal models for the study of the role of hypoxia in metastases and develop a bio-bank of tumour and blood samples for molecular diagnostic studies. We will identify and develop advanced imaging techniques and biomarkers and identify micro-metastases in bone marrow of patients to assist in the selection of appropriate stratification of the actual primary tumour’s and metastases’ micro-environmental conditions. We will also create a machine-learning based classifier of tumour hypoxia. The consortium has the necessary expertise to perform proof-of-principle clinical testing of new treatment strategies. We will thus perform clinical tests of new drugs developed to attack the regulatory mechanisms selected from the pre-clinical work and possible synergisms of combined treatments. We will also test new radiotherapy strategies for treatment of primary as well as metastatic tumours. Cancer types chosen for clinical studies are non-small-cell lung carcinoma, squamous cell carcinoma of the larynx, prostate cancer, primary breast cancer and rectal cancer.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITETET I OSLO

Address

Problemveien 5-7
0313 Oslo

Norway

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 192 200

Administrative Contact

Lars Bernhardsen (Mr.)

Participants (20)

Sort alphabetically

Sort by EU Contribution

Expand all

STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC

Netherlands

EU Contribution

€ 471 800

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 648 100

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 572 500

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 584 500

AARHUS UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 574 900

FMC BIOPOLYMER AS

Norway

EU Contribution

€ 296 500

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 746 500

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 547 300

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 775 100

UNIVERSIDAD AUTONOMA DE MADRID

Spain

EU Contribution

€ 420 100

DEUTSCHES HERZZENTRUM MUNCHEN

Germany

EU Contribution

€ 427 300

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 428 500

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

EU Contribution

€ 429 700

JOBST TECHNOLOGIES GMBH

Germany

EU Contribution

€ 295 300

ViVoX ApS

Denmark

EU Contribution

€ 298 900

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 373 200

VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED

Slovakia

EU Contribution

€ 412 900

VILNIAUS UNIVERSITETAS

Lithuania

EU Contribution

€ 279 700

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 438 300

OSLO UNIVERSITETSSYKEHUS HF

Norway

EU Contribution

€ 785 000

Project information

Grant agreement ID: 222741

Status

Closed project

  • Start date

    1 February 2009

  • End date

    31 July 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 038 623,20

  • EU contribution

    € 11 998 300

Coordinated by:

UNIVERSITETET I OSLO

Norway

This project is featured in...